Regor Begins Phase 2 Trial for RGT-075

Regor Begins Phase 2 Trial for RGT-075

By, Admin 12 March 2024

Regor initiates phase 2 study of oral once-daily GLP-1 agonist RGT-075 to treat obesity

Regor Therapeutics Group (Regor), a clinical-stage global biopharmaceutical company, announced that its phase 2 trial of the highly selective oral GLP-1 agonist RGT-075 is initiated in adults with obesity or overweight with weight-related comorbidities and has First Patient First Visit (FPFV) on March 08, 2024.

Words from MD: Regor

  • The topline results for this phase 2 trial are expected to be announced in the second half of 2024. “The initiation of the phase 2 trial marks an important milestone in the development of RGT-075 as we believe it could represent a convenient and potentially meaningful alternative to the currently available weight loss treatments,” said Michael Grimm, M.D., Ph.D., head of metabolic diseases at Regor. 
  • “RGT-075 is designed to be administered orally once daily as a monotherapy or as part of a potential oral combination treatment for obesity. Phase 1 clinical data showed promising exploratory body weight trends despite short treatment duration,” added Dr. Grimm.

About Trial

  • The phase 2 multicenter, randomized, double-blind, placebo-controlled study is designed to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of once-daily oral RGT-075 compared with placebo in adult patients with obesity or overweight with weight-related comorbidities. 
  • Approximately 60 adult participants with a BMI = 27 kg/m2 and = 45 kg/m2 will be enrolled and randomized to RGT-075 or placebo. 
  • The treatment will last 12 weeks; all participants on RGT001-075 will be given RGT-075 once daily (QD) titrated up over 6 weeks, then being maintained with the target dose for 6 weeks. 
  • Topline data from the phase 2 study are expected to be announced in the second half of 2024.

About RGT-075

  • RGT-075 is an oral-available, once-daily, small molecule GLP-1R full agonist discovered and developed by Regor for the treatment of metabolic diseases, such as type-2 diabetes mellitus and overweight/obesity. 
  • Regor completed its phase 1 single ascending dose (SAD) and multiple ascending dose (MAD) studies. 
  • RGT-075 was safe and clinically well-tolerated in clinical trials completed to date.

About Regor Therapeutics

  • Regor Therapeutics is a global biotech company founded in 2018 by a team of scientists with a proven track record in drug discovery and executive leadership covering full cycle of drug discovery and development. 
  • By leveraging its industry-leading core strength in rCARD (Computer Accelerated Rational Discovery), Regor has completed 8 PCCs inhouse, with 5 INDs filed, validating Regor’s highly efficient ecosystem for accelerated discovery of innovative therapeutic agents.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!